Necrotizing Fasciitis—Severe Complication of Bullous Pemphigoid: A Systematic Review, Risk Factors, and Treatment Challenges
<i>Background and objectives:</i> Bullous pemphigoid (BP), the most common subepidermal autoimmune skin blistering disease (AIBD) has an estimated annual incidence of 2.4 to 42.8 new cases per million in different populations, designating it an orphan disease. Characterized by disruption...
Main Authors: | Milan Stojičić, Milana Jurišić, Milana Marinković, Miodrag Karamarković, Milan Jovanović, Jelena Jeremić, Marko Jović, Aleksandar Vlahović, Mladen Jovanović, Kristina Radenović, Nikola Jovićević, Dolika Vasović |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Medicina |
Subjects: | |
Online Access: | https://www.mdpi.com/1648-9144/59/4/745 |
Similar Items
-
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
by: Roberto Russo, et al.
Published: (2022-06-01) -
Evaluation of ELISA BP180 and BP230 Autoantibodies in Blister Fluid and Serum in the Diagnosis of Bullous Pemphigoid
by: Harish Nagarajan, et al.
Published: (2023-01-01) -
Emerging treatments for bullous pemphigoid
by: Pedro Miguel Garrido, et al.
Published: (2022-02-01) -
Bullous eczema presenting as bullous pemphigoid-like eruption: A case series
by: George Atteh, BS, et al.
Published: (2021-04-01) -
From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid
by: Belen de Nicolas-Ruanes, et al.
Published: (2023-11-01)